Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 10/20 | 0.72 |
| ▸ | FNTA | P49354 | 9/20 | 0.46 |
| ▸ | FNTB | P49356 | 7/20 | 0.46 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL570052 | 1.00 | BTN3A1 (0.72) | BTN3A1FNTAFNTBPGGT1B | |
| Phosphoric Acid SCHEMBL27686050 | 0.98 | BTN3A1 (0.70) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL30169833 | 0.89 | BTN3A1 (0.60) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL23455691 | 0.84 | BTN3A1 (0.63) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL83423 | 0.84 | BTN3A1 (1.00) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL14387716 | 0.84 | BTN3A1 (1.00) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL254662 | 0.84 | BTN3A1 (1.00) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL13485664 | 0.83 | BTN3A1 (0.62) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL8439565 | 0.83 | BTN3A1 (0.52) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL13485448 | 0.82 | BTN3A1 (0.61) | BTN3A1FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117794581-A | Conjugates comprising phosphoantigen and their use in therapy | 拜奥迪斯私人有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20240043493-A1 | ACYLATED SINGLE-CHAIN INSULIN ANALOGUES | CASE WESTERN RESERVE UNIVERSITY | 2024-02-08 | — | — | US | disclosed |
| EP-4255469-A1 | ACYLATED SINGLE-CHAIN INSULIN ANALOGUES | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-10-11 | — | — | EP | disclosed |
| WO-2022125587-A9 | ACYLATED SINGLE-CHAIN INSULIN ANALOGUES | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-07-21 | — | — | WO | disclosed |
| WO-2022125587-A1 | ACYLATED SINGLE-CHAIN INSULIN ANALOGUES | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20210171552-A1 | PHOSPHOANTIGEN PRODRUG COMPOUNDS | UNIVERSITY OF BIRMINGHAM (GB) | 2021-06-10 | — | — | US | disclosed |
| CN-104471061-A | Isoprene synthase and polynucleotide encoding same, and method for producing isoprene monomer | BRIDGESTONE CORP | 2015-03-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171552-A1 | PHOSPHOANTIGEN PRODRUG COMPOUNDS | CD4, CD47, CD69 | BTN3A1 711/4885FNTA 1115/4885FNTB 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.